NL300372I1 - Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen - Google Patents

Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen

Info

Publication number: NL300372I1
Authority: NL; Netherlands
Prior art keywords: therapeutic methods; hybrid immunoglobulins; methods; useful; peptides
Prior art date: 1989-11-22

Application number

NL300372C

Other languages

English (en)

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-22

Filing date

2008-11-27

Publication date

2009-02-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23749509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300372(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-27 Application filed by Genentech Inc filed Critical Genentech Inc

2009-02-02 Publication of NL300372I1 publication Critical patent/NL300372I1/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Physics & Mathematics (AREA)
Neurology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)

NL300372C 1989-11-22 2008-11-27 Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen NL300372I1 (nl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/440,625 US5116964A (en)	1989-02-23	1989-11-22	Hybrid immunoglobulins

Publications (1)

Publication Number	Publication Date
NL300372I1 true NL300372I1 (nl)	2009-02-02

Family

ID=23749509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL300372C NL300372I1 (nl)	1989-11-22	2008-11-27	Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen

Country Status (12)

Country	Link
US (1)	US5116964A (nl)
EP (3)	EP1970386A2 (nl)
JP (2)	JPH05503009A (nl)
AT (2)	ATE396735T1 (nl)
CA (1)	CA2072642C (nl)
DE (3)	DE122008000063I2 (nl)
DK (2)	DK1029870T3 (nl)
ES (2)	ES2308826T3 (nl)
GR (1)	GR3035856T3 (nl)
LU (1)	LU91498I2 (nl)
NL (1)	NL300372I1 (nl)
WO (1)	WO1991008298A2 (nl)

Families Citing this family (633)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
US6018026A (en)	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) *	1988-01-22	1998-05-12	Zymogenetics, Inc.	Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) *	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6685941B1 (en)	1988-11-23	2004-02-03	The Regents Of The University Of Michigan	Methods of treating autoimmune disease via CTLA-4Ig
US6406697B1 (en)	1989-02-23	2002-06-18	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5242687A (en) *	1989-03-15	1993-09-07	Tkb Associates Limited Partnership	Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
ES2238070T3 (es)	1989-04-21	2005-08-16	Amgen Inc.	Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US7264944B1 (en)	1989-04-21	2007-09-04	Amgen Inc.	TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) *	1989-07-18	2000-11-07	Amgen, Inc.	Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en)	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
US6267964B1 (en) *	1989-08-01	2001-07-31	Affibody Technology Sweden Ab	Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5605690A (en) *	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6541610B1 (en) *	1989-09-05	2003-04-01	Immunex Corporation	Fusion proteins comprising tumor necrosis factor receptor
US5945397A (en) *	1989-09-05	1999-08-31	Immunex Corporation	Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) *	1989-09-05	1995-03-07	Immunex Corporation	DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en)	1989-09-05	1991-12-23	Immunex Corp	Tumour necrosis factor receptor protein and dna sequences
DE59010908D1 (de) *	1989-09-12	2000-08-10	Hoffmann La Roche	TNF-bindende Proteine
US5216132A (en) *	1990-01-12	1993-06-01	Protein Design Labs, Inc.	Soluble t-cell antigen receptor chimeric antigens
US6552170B1 (en) *	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
GB9022543D0 (en) *	1990-10-17	1990-11-28	Wellcome Found	Antibody production
DE4037837A1 (de) *	1990-11-28	1992-06-04	Behringwerke Ag	Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
US7070991B2 (en) *	1991-02-08	2006-07-04	Progenics Pharmaceuticals, Inc.	Cells expressing a CD4-IgG2 chimeric heterotetramer
WO1992013947A1 (en)	1991-02-08	1992-08-20	Progenics Pharmaceuticals, Inc.	CD4-GAMMA2 AND CD4-IgG2 CHIMERAS
MX9203138A (es) *	1991-03-12	1992-09-01	Biogen Inc	Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
CA2081028C (en) *	1991-03-12	1999-12-14	Barbara P. Wallner	Cd2 binding domain of lymphocyte function associated antigen 3
US20030206899A1 (en) *	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
US6582959B2 (en) *	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US5318890A (en) *	1991-05-06	1994-06-07	The Regents Of The University Of California	Assays for inhibitors of leukocyte adhesion
US6797492B2 (en)	1991-05-17	2004-09-28	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
EP0533006A1 (en) *	1991-09-18	1993-03-24	F.Hoffmann-La Roche & Co. Aktiengesellschaft	Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US6764681B2 (en) *	1991-10-07	2004-07-20	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US6399368B1 (en)	1992-01-17	2002-06-04	Board Of Regents, The University Of Texas System	Secretion of T cell receptor fragments from recombinant Escherichia coli cells
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993019777A1 (en) *	1992-03-30	1993-10-14	Immunex Corporation	Fusion proteins comprising tumor necrosis factor receptor
EP0640094A1 (en) *	1992-04-24	1995-03-01	The Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5540926A (en) *	1992-09-04	1996-07-30	Bristol-Myers Squibb Company	Soluble and its use in B cell stimulation
WO1994005314A1 (en) *	1992-09-08	1994-03-17	Centocor, Inc.	Peptide inhibitors of leukocyte adhesion
NZ256293A (en) *	1992-09-15	1997-06-24	Immunex Corp	Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
DE69310525T2 (de) *	1992-09-16	1997-10-02	Genentech Inc	Schutz gegen leberschäden mit hgf
WO1994006469A1 (en) *	1992-09-18	1994-03-31	La Jolla Institute For Allergy And Immunology	Hiv fusion polypeptide
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5474766A (en) *	1992-12-18	1995-12-12	Washington University	Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
US5710123A (en) *	1992-12-18	1998-01-20	Centocor, Inc.	Peptide inhibitors of selectin binding
NZ261991A (en) *	1993-01-25	1998-04-27	Dana Farber Cancer Inst Inc	Chimeric l and p selectin made by exchange of domains, uses thereof
US7534867B1 (en)	1993-05-19	2009-05-19	Schering Corporation	Purified mammalian Flt3 ligands; agonists; antagonists
US6824779B1 (en)	1993-07-26	2004-11-30	Dana-Farber Cancer Institute, Inc.	Methods for inhibiting the interaction of B7-2 with its natural ligand
US20050129670A1 (en) *	1993-07-26	2005-06-16	Genetics Institute, Llc.	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6130316A (en) *	1993-07-26	2000-10-10	Dana Farber Cancer Institute	Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5861310A (en) *	1993-11-03	1999-01-19	Dana-Farber Cancer Institute	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6723705B1 (en)	1993-08-19	2004-04-20	Gentics Institute, Inc.	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6084067A (en) *	1993-07-26	2000-07-04	Dana-Farber Cancer Institute	CTLA4/CD28 ligands and uses therefor
SE9302855D0 (sv) *	1993-09-06	1993-09-06	Martin Lindberg	Method and means for producing plasmaproteinase inhibitor binding proteins
WO1995014787A1 (en) *	1993-11-22	1995-06-01	Centocor, Inc.	Peptide inhibitors of selecting binding
JPH09509054A (ja) *	1994-02-01	1997-09-16	アメリカ合衆国	抗体部分および非抗体部分を含む融合タンパク質
US7294331B2 (en) *	1994-03-07	2007-11-13	Immunex Corporation	Methods of using flt3-ligand in hematopoietic cell transplantation
ES2153895T3 (es)	1994-03-08	2001-03-16	Dana Farber Cancer Inst Inc	Metodos para modular la insensibilidad de celulas t.
US5877016A (en)	1994-03-18	1999-03-02	Genentech, Inc.	Human trk receptors and neurotrophic factor inhibitors
IL113484A0 (en) *	1994-04-28	1995-07-31	Immunex Corp	Viral proteins pharmaceutical compositions containing them their preparation and use
IL113617A (en)	1994-05-06	2007-09-20	Florence Faure	Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) *	1994-08-17	2000-04-11	The Rockefeller University	OB polypeptides as modulators of body weight
US6471956B1 (en)	1994-08-17	2002-10-29	The Rockefeller University	Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en)	1994-08-17	2002-02-26	The Rockefeller University	OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en)	1994-08-17	2002-08-06	The Rockefeller University	OB polypeptides, modified forms and derivatives
US6124448A (en) *	1994-08-17	2000-09-26	The Rockfeller University	Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en)	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US5814464A (en) *	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
US6410008B1 (en) *	1994-12-12	2002-06-25	Beth Israel Hospital Association	Chimeric IL-10 proteins and uses thereof
WO1996018412A1 (en) *	1994-12-12	1996-06-20	Beth Israel Hospital Association	Chimeric cytokines and uses thereof
US6808709B1 (en) *	1994-12-30	2004-10-26	The Regents Of The University Of California	Immunoglobulins containing protection proteins and their use
US6030613A (en) *	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6485726B1 (en)	1995-01-17	2002-11-26	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6086875A (en) *	1995-01-17	2000-07-11	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of immunogens
US6455685B1 (en)	1995-03-03	2002-09-24	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of immune disorders
US20030069196A1 (en) *	1995-03-03	2003-04-10	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of immune disorders
US6066322A (en) *	1995-03-03	2000-05-23	Millennium Pharmaceuticals, Inc.	Methods for the treatment of immune disorders
US6211142B1 (en) *	1995-03-10	2001-04-03	Genentech, Inc.	Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US6680057B1 (en) *	1995-03-23	2004-01-20	Immunex Corporation	Methods of treating autoimmune disease by administering interleukin-17 receptor
JP4373495B2 (ja) *	1995-03-23	2009-11-25	イミュネックス・コーポレーション	Ｉｌ−１７受容体
US20060193862A1 (en) *	1995-03-30	2006-08-31	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
IL117645A (en) *	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US7175847B1 (en) *	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) *	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) *	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US20020034517A1 (en) *	1995-10-04	2002-03-21	Kenneth Brasel	Dendritic cell stimulatory factor
US7361330B2 (en) *	1995-10-04	2008-04-22	Immunex Corporation	Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en)	1995-10-04	2006-12-19	Innunex Corporation	Methods of preparing dendritic cells with flt3-ligand and antigen
US6936439B2 (en) *	1995-11-22	2005-08-30	Amgen Inc.	OB fusion protein compositions and methods
US20030040467A1 (en) *	1998-06-15	2003-02-27	Mary Ann Pelleymounter	Ig/ob fusions and uses thereof.
US20030026779A1 (en) *	1999-10-15	2003-02-06	Liming Yu	Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US20020193571A1 (en)	1996-01-08	2002-12-19	Paul J. Carter	Wsx receptor agonist antibodies
US6750334B1 (en) *	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5917026A (en) *	1996-02-05	1999-06-29	Loewenadler; Bjoern	Fusion proteins of immunopotentiating activity
ATE448797T1 (de)	1996-02-09	2009-12-15	Amgen Inc	Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
EA002474B1 (ru) *	1996-02-20	2002-06-27	Апплайд Резеч Системз Арс Холдинг Н.В.	Гибридный белок, образующий гетеродимеры, способ его получения и использования
US6194177B1 (en) *	1996-02-20	2001-02-27	Applied Research Systems Ars Holding N.V.	DNA encoding a hybrid heterodimeric protein
GB9604518D0 (en) *	1996-03-02	1996-05-01	Smithkline Beecham Plc	Novel compounds
WO1997035991A1 (en) *	1996-03-28	1997-10-02	The Johns Hopkins University	Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en)	1996-03-28	2002-10-01	The Johns Hopkins University	Molecular complexes which modify immune responses
US6140305A (en) *	1996-04-04	2000-10-31	Bio-Rad Laboratories, Inc.	Hereditary hemochromatosis gene products
US7026116B1 (en) *	1996-04-04	2006-04-11	Bio-Rad Laboratories, Inc.	Polymorphisms in the region of the human hemochromatosis gene
US7063965B2 (en) *	1996-04-05	2006-06-20	Regeneron Pharmaceuticals, Inc.	Nucleic acid encoding TIE-2 ligand
US6060054A (en)	1996-04-10	2000-05-09	National Jewish Medical And Research Center	Product for T lymphocyte immunosuppression
US6117977A (en) *	1996-04-24	2000-09-12	Genentech, Inc.	Type C lectins
US6451308B1 (en)	1996-04-26	2002-09-17	Beth Israel Deaconess Medical Center	Antagonists of interleukin-15
EP0927254B1 (en) *	1996-04-26	2005-06-22	Beth Israel Deaconess Medical Center, Inc.	Antagonists of interleukin-15
WO1997042319A1 (fr) *	1996-05-02	1997-11-13	Mochida Pharmaceutical Co., Ltd.	NOUVEAUX DERIVES DE L'ANTIGENE Fas
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6849399B1 (en)	1996-05-23	2005-02-01	Bio-Rad Laboratories, Inc.	Methods and compositions for diagnosis and treatment of iron misregulation diseases
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DE69732711T2 (de) *	1996-07-12	2006-03-16	Genentech, Inc., South San Francisco	Gamma-heregulin
CN1202247C (zh) *	1996-07-12	2005-05-18	基因技术股份有限公司	嵌合异源多亚基粘附素
US6159462A (en) *	1996-08-16	2000-12-12	Genentech, Inc.	Uses of Wnt polypeptides
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
ATE247974T1 (de)	1996-12-06	2003-09-15	Amgen Inc	Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
WO1998024477A1 (en)	1996-12-06	1998-06-11	Amgen Inc.	Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US20030171551A1 (en) *	1997-01-31	2003-09-11	Joseph D. Rosenblatt	Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6268411B1 (en)	1997-09-11	2001-07-31	The Johns Hopkins University	Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US7435793B2 (en) *	1998-05-15	2008-10-14	Genentech, Inc.	Peptides that induce chondrocyte redifferentiation
US20020137890A1 (en) *	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2288430C (en)	1997-04-16	2013-04-09	Millennium Biotherapeutics, Inc.	Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
US6190909B1 (en) *	1997-04-17	2001-02-20	Millennium Pharmaceuticals, Inc.	TH2-specific gene
CA2288351A1 (en) *	1997-05-01	1998-11-05	Amgen Inc.	Chimeric opg polypeptides
US20020062010A1 (en) *	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) *	1997-05-02	2011-05-31	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
ATE299938T1 (de) *	1997-05-02	2005-08-15	Genentech Inc	Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20030207346A1 (en) *	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
CA2293808C (en)	1997-06-13	2006-10-17	Progenitor, Inc.	Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
US20030054987A1 (en) *	1997-06-16	2003-03-20	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040191256A1 (en) *	1997-06-24	2004-09-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
KR100220645B1 (ko) *	1997-07-04	1999-09-15	구광시	벤젠유도체의 제조방법
US6165476A (en) *	1997-07-10	2000-12-26	Beth Israel Deaconess Medical Center	Fusion proteins with an immunoglobulin hinge region linker
US6242570B1 (en)	1997-07-10	2001-06-05	Beth Israel Deaconess Medical Center	Production and use of recombinant protein multimers with increased biological activity
US6187564B1 (en)	1997-07-10	2001-02-13	Beth Israel Deaconess Medical Center	DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US20030166188A1 (en) *	1997-09-18	2003-09-04	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) *	1998-03-17	2002-05-21	Genentech, Inc.	Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US6503184B1 (en)	1997-10-21	2003-01-07	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en)	1997-10-21	2004-02-10	Human Genome Sciences, Inc.	Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
EP1025228A4 (en) *	1997-10-21	2002-09-18	Human Genome Sciences Inc	HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
US20040136986A1 (en) *	1997-10-31	2004-07-15	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
US6576743B1 (en) *	1997-11-26	2003-06-10	Zymogenetics, Inc.	Mammalian cytokine-like polypeptide-10
DK1037927T3 (da)	1997-12-08	2004-09-06	Emd Lexigen Res Ct Corp	Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US6207413B1 (en) *	1998-01-22	2001-03-27	Regeneron Pharmaceuticals, Inc.	Nucleic acids encoding novel orphan cytokine receptors
US20030105294A1 (en) *	1998-02-25	2003-06-05	Stephen Gillies	Enhancing the circulating half life of antibody-based fusion proteins
US7198789B2 (en) *	1998-03-17	2007-04-03	Genetics Institute, Llc	Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) *	1998-03-17	2000-05-02	Genetics Institute, Inc.	MU-1, member of the cytokine receptor family
US7189400B2 (en) *	1998-03-17	2007-03-13	Genetics Institute, Llc	Methods of treatment with antagonists of MU-1
US7723488B2 (en) *	1998-03-27	2010-05-25	Genentech, Inc.	Monoclonal antibodies to secreted and transmembrane polypeptides
US7371836B2 (en) *	1998-03-27	2008-05-13	Genentech, Inc.	PRO526 nucleic acids
WO1999052562A2 (en) *	1998-04-15	1999-10-21	Lexigen Pharmaceuticals Corp.	Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP2333069A3 (en) *	1998-05-15	2011-09-14	Genentech, Inc.	Therapeutic uses of IL-17 homologous polypeptides
US7125959B2 (en) *	1998-05-15	2006-10-24	Genentech, Inc.	PRO4405 polypeptides
PT1086138E (pt)	1998-06-12	2010-01-04	Genentech Inc	Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
WO1999066054A2 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corp.	Erythropoietin analog-human serum albumin fusion protein
US20070003545A9 (en) *	1999-06-02	2007-01-04	Eaton Dan L	Interleukin-8 homologous polypeptides and therapeutic uses thereof
US20030065154A1 (en) *	2000-03-30	2003-04-03	Genentech, Inc.	Interleukin-8 homologous polypeptides and therapeutic uses thereof
US7339033B2 (en) *	1998-06-26	2008-03-04	Genentech, Inc.	Pro1481
US20020099197A1 (en) *	1998-07-21	2002-07-25	Rory A.J. Curtis	Novel potassium channel molecules and uses therefor
PL346339A1 (en) *	1998-08-31	2002-02-11	Biogen	Method of modulating memory effector t-cells and compositions
NZ510689A (en) *	1998-10-16	2003-07-25	Biogen Inc	Polymer conjugates of interferon beta-1a and uses
AU766190B2 (en) *	1998-10-16	2003-10-09	Biogen Idec Ma Inc.	Interferon-beta fusion proteins and uses
US6660843B1 (en) †	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
WO2000024770A2 (en) *	1998-10-23	2000-05-04	Amgen Inc.	Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7488590B2 (en) *	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
WO2000027885A1 (fr) *	1998-11-05	2000-05-18	Kyowa Hakko Kogyo Co., Ltd.	Nouveau popypeptide chimerique
EP1129193A4 (en) *	1998-11-10	2005-08-10	Human Genome Sciences Inc	CHEMOKIN BETA-7
US7294482B2 (en) *	1998-11-19	2007-11-13	Millennium Pharmaceuticals, Inc.	EGF-like nucleic acids
US7235642B1 (en) *	1999-01-12	2007-06-26	Genentech, Inc.	Anti-PRO 1313 antibodies
US6656728B1 (en)	1999-02-08	2003-12-02	Chiron Corporation	Fibroblast growth factor receptor-immunoglobulin fusion
JP2002540078A (ja)	1999-03-19	2002-11-26	ジェネンテック・インコーポレーテッド	Ｌｆａ−１アンタゴニスト投与量の増加によるｌｆａ−１関連疾患の治療
US7011833B1 (en) *	1999-05-06	2006-03-14	Genetics Institute, Inc.	Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
US20050079577A1 (en) *	1999-05-14	2005-04-14	Ashkenazi Avi J.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1187852T3 (da) *	1999-05-19	2007-11-26	Merck Patent Gmbh	Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
CA2375700A1 (en) *	1999-06-01	2000-12-07	Biogen, Inc.	Polymer conjugates of hedgehog proteins and uses
AU5309600A (en) *	1999-06-02	2000-12-18	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of immune disorders
US6924359B1 (en) *	1999-07-01	2005-08-02	Yale University	Neovascular-targeted immunoconjugates
AU779612C (en)	1999-07-02	2005-12-15	Genentech Inc.	Peptide compounds that bind HER2
IL147269A0 (en) *	1999-07-02	2002-08-14	Genentech Inc	FVIIa ANTAGONISTS
CA2378796A1 (en) *	1999-07-12	2001-01-18	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Seripancrin
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001007084A1 (en) *	1999-07-23	2001-02-01	Regents Of The University Of California	Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
EP1203014B1 (en) *	1999-08-06	2004-10-13	Genentech, Inc.	Peptide antagonists of factor viia
JP4793971B2 (ja)	1999-08-09	2011-10-12	メルクパテントゲーエムベーハー	複合サイトカイン−抗体複合体
DK1210428T3 (en)	1999-08-23	2015-06-15	Dana Farber Cancer Inst Inc	PD-1, a receptor for B7-4 AND USE THEREOF
US20020173627A1 (en) *	1999-09-16	2002-11-21	Samuel Davis	TIE-2 ligands, methods of making and uses thereof
US6323334B1 (en) *	1999-09-24	2001-11-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding a 103 gene product and uses therefor
CA2390166C (en) *	1999-11-05	2011-03-22	Biogen, Inc.	Hedgehog fusion proteins and uses
JP2003514552A (ja)	1999-11-12	2003-04-22	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) *	1999-11-12	2005-09-15	Merck Patent Gmbh	Fc-erythropoietin fusion protein with improved pharmacokinetics
US7122632B2 (en) *	1999-12-23	2006-10-17	Zymogenetics, Inc.	Soluble Interleukin-20 receptor
US7307153B2 (en) *	1999-12-23	2007-12-11	Genentech, Inc.	Antibodies that bind PRO9912
US6610286B2 (en)	1999-12-23	2003-08-26	Zymogenetics, Inc.	Method for treating inflammation using soluble receptors to interleukin-20
US7164001B2 (en) *	2000-01-20	2007-01-16	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
AU4314801A (en)	2000-02-11	2001-08-20	Lexigen Pharm Corp	Enhancing the circulating half-life of antibody-based fusion proteins
EA005583B1 (ru) *	2000-02-21	2005-04-28	Апплайд Резеч Системз Арс Холдинг Н.В.	Применение ингибиторов il-18
US7541184B2 (en) *	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en) *	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6984519B2 (en)	2000-03-01	2006-01-10	Genetech, Inc.	Nucleic acids encoding peptides that induce chondrocyte redifferentiation
US20060073547A1 (en) *	2000-03-01	2006-04-06	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060002943A1 (en) *	2000-03-02	2006-01-05	Genentech, Inc.	Compositions and methods for the treatment of tumor of hematopoietic origin
US20020064820A1 (en) *	2000-03-13	2002-05-30	Jean-Michel Dayer	Apo-A-I regulation of T-cell signaling
US7514239B2 (en) *	2000-03-28	2009-04-07	Amgen Inc.	Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
CA2405800A1 (en) *	2000-04-10	2001-10-18	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Novel secreted protein
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2001274809A1 (en) *	2000-04-12	2001-10-30	Human Genome Sciences, Inc.	Albumin fusion proteins
CN1437478A (zh) *	2000-04-25	2003-08-20	Idec药物公司	瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
US6756480B2 (en)	2000-04-27	2004-06-29	Amgen Inc.	Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20060015969A1 (en) *	2000-04-28	2006-01-19	Planet Biotechnology, Inc.	Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
WO2001083529A2 (en) *	2000-04-28	2001-11-08	Planet Biotechnology, Inc.	Immunoadhesin for the prevention of rhinovirus infection
JP2003533187A (ja) *	2000-05-03	2003-11-11	アムジエン・インコーポレーテツド	治療薬としてのＦｃドメインを含む修飾ペプチド
US20020102232A1 (en) *	2000-05-11	2002-08-01	Chang Tse W.	Compositions and methods for induction of active autoimmunity
AU2001261585B2 (en)	2000-05-12	2006-08-31	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for achieving immune suppression
EP1714661A3 (en)	2000-05-19	2012-03-14	The Center for Blood Research, INC.	Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US20040034193A1 (en) *	2001-06-13	2004-02-19	Samy Ashkar	Biosynthetic oncolytic molecules and uses therefor
US20050048614A1 (en) *	2000-06-13	2005-03-03	Children's Medical Center Corporation	Biosynthetic oncolytic molecules and uses therefor
JP2004501628A (ja) *	2000-06-26	2004-01-22	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体ｚｃｙｔｏｒ１７
US20030096339A1 (en) *	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
AU7309601A (en)	2000-06-28	2002-01-08	Genetics Inst	Pd-l2 molecules: novel pd-1 ligands and uses therefor
RU2272644C2 (ru) *	2000-06-29	2006-03-27	Мерк Патент Гмбх	Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP2177616B1 (en) *	2000-08-08	2012-02-29	ZymoGenetics, Inc.	Soluble zcytor 11 cytokine receptors
US20030215916A1 (en) *	2000-08-18	2003-11-20	Feder John N.	Novel imidazoline receptor homologs
US20020119148A1 (en)	2000-09-01	2002-08-29	Gerritsen Mary E.	ErbB4 antagonists
ATE448306T1 (de)	2000-09-01	2009-11-15	Blood Res Center	Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
DE60138222D1 (de) *	2000-09-14	2009-05-14	Beth Israel Hospital	Modulierung von il-2 und il-15 vermittelten t zellantworten
EP1366078B1 (en)	2000-09-26	2008-07-30	Genentech, Inc.	Ige receptor antagonists
AU2001294913A1 (en) *	2000-09-29	2002-04-08	Bristol-Myers Squibb Company	Identification and cloning of a full-length human cink-related gene, mist (mast cell immunoreceptor signal transducer)
US20030211549A1 (en) *	2000-10-06	2003-11-13	Murphy Andrew J.	Functional proteins and therapeutic and diagnostic methods for use thereof
AU2002237733A1 (en) *	2000-11-07	2002-06-18	Board Of Regents, The University Of Texas System	Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
WO2002045739A1 (en) *	2000-12-04	2002-06-13	Auckland Uniservices Limited	Immunomodulatory constructs and their uses
US7396917B2 (en)	2000-12-05	2008-07-08	Alexion Pharmaceuticals, Inc.	Rationally designed antibodies
US20040253242A1 (en) *	2000-12-05	2004-12-16	Bowdish Katherine S.	Rationally designed antibodies
ATE544785T1 (de) *	2000-12-05	2012-02-15	Alexion Pharma Inc	Rationell entworfene antikörper
US7056737B2 (en) *	2001-02-16	2006-06-06	Bristol-Myers Squibb Company	Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof
PL206701B1 (pl) *	2001-03-07	2010-09-30	Merck Patent Gmbh	Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US8163289B2 (en)	2001-03-09	2012-04-24	Iterative Therapeutics, Inc.	Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2002072608A2 (en)	2001-03-09	2002-09-19	University Of Chicago	POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
US6992174B2 (en) *	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
MXPA03008959A (es)	2001-04-02	2004-10-15	Wyeth Corp	Pd-1, un receptor para b7-4 y sus usos.
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
ITRE20010042A1 (it) *	2001-04-24	2002-10-24	Corghi Spa	Dispositivo sollevatore per macchine smontagomme
US20050089932A1 (en) *	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
US7265208B2 (en) *	2001-05-01	2007-09-04	The Regents Of The University Of California	Fusion molecules and treatment of IgE-mediated allergic diseases
DE60239454D1 (de) *	2001-05-03	2011-04-28	Merck Patent Gmbh	Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
DK1385882T3 (da)	2001-05-11	2008-02-11	Amgen Inc	Peptider og relaterede molekyler, der binder til TALL-1
EP1478748A4 (en) *	2001-06-15	2005-09-21	Tanox Inc	FCE FUSION PROTEINS FOR THE TREATMENT OF ALLERGIES AND ASTHMA
US20060073141A1 (en) *	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
WO2003009740A2 (en) *	2001-07-24	2003-02-06	Biogen Idec Ma Inc.	Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2003015697A2 (en) *	2001-08-13	2003-02-27	University Of Southern California	Interleukin-2 mutants with reduced toxicity
US6900292B2 (en) *	2001-08-17	2005-05-31	Lee-Hwei K. Sun	Fc fusion proteins of human erythropoietin with increased biological activities
ES2386346T3 (es)	2001-08-29	2012-08-17	Genentech, Inc.	Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena
DK1427750T3 (da) *	2001-08-30	2011-02-14	Biorexis Pharmaceutical Corp	Modificerede transferrin-fusionsproteiner
US6797493B2 (en)	2001-10-01	2004-09-28	Lee-Hwei K. Sun	Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
AU2002332041A1 (en) *	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
US7205275B2 (en) *	2001-10-11	2007-04-17	Amgen Inc.	Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) *	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
CA2463003A1 (en) *	2001-10-19	2003-04-24	Zymogenetics, Inc.	Dimerized growth factor and materials and methods for producing it
WO2003040311A2 (en) *	2001-10-25	2003-05-15	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20070118934A1 (en) *	2001-10-26	2007-05-24	Planet Biotechnology, Inc.	Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
RU2312677C9 (ru) *	2001-12-04	2008-03-27	Мерк Патент Гмбх	Иммуноцитокины с модулированной селективностью
AU2002361385B2 (en) *	2001-12-18	2009-11-19	Centre National De La Recherche Scientifique Cnrs	Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
US7858297B2 (en)	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
EP2990417A1 (en)	2001-12-21	2016-03-02	Human Genome Sciences, Inc.	Albumin insulin fusion protein
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
WO2003059934A2 (en) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2003210564B2 (en) *	2002-01-18	2008-10-23	Biogen Ma Inc.	Polyalkylene glycol with moiety for conjugating biologically active compound
ES2351678T3 (es)	2002-01-18	2011-02-09	Zymogenetics, Inc.	Ligando de citocina para el tratamiento de asma e hiper-sensibilidad de las vías respiratorias .
US7164002B2 (en)	2002-02-06	2007-01-16	Genentech, Inc.	FVIIa antagonists
US20030211470A1 (en) *	2002-03-15	2003-11-13	Olson William C.	CD4-IgG2-based salvage therapy of HIV-1 infection
EA200401342A1 (ru) *	2002-04-10	2005-08-25	Апплайд Резеч Системз Арс Холдинг Н. В.	Новые антагонисты белков mcp
US20040016010A1 (en) *	2002-04-17	2004-01-22	Marion Kasaian	IL-21 receptor knockout animal and methods of use thereof
WO2003100056A1 (fr)	2002-05-29	2003-12-04	Yamasa Corporation	Nouvelle enzyme polyphosphate :amp phosphotransferase
WO2003101485A1 (en) *	2002-05-30	2003-12-11	Macrogenics, Inc.	Cd16a binding proteins and use for the treatment of immune disorders
NZ519371A (en) *	2002-06-04	2004-11-26	Auckland Uniservices Ltd	Immunomodulatory constructs and their uses
US20090130021A1 (en) *	2002-06-07	2009-05-21	Gotz Munch	Methods, products and uses involving platelets and/or the vasculature
US7531178B2 (en) *	2002-06-07	2009-05-12	Trigen Gmbh	Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) *	2002-06-07	2003-12-10	Procorde GmbH	Inhibitors of glycoprotein VI and their therapeutic use
US20070071744A1 (en) *	2002-06-07	2007-03-29	Gotz Munch	Agents which bind to epitopes of glycoprotein VI
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
US8025873B2 (en) *	2002-06-20	2011-09-27	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
EP1545608A4 (en)	2002-06-28	2006-09-13	Centocor Inc	CH1-DELETED MAMMED MUICETIC BODIES, COMPOSITIONS, METHODS AND APPLICATIONS
EP2135879A3 (en) *	2002-06-28	2010-06-23	Domantis Limited	Ligand
US20070104710A1 (en) *	2002-06-28	2007-05-10	Domants Limited	Ligand that has binding specificity for IL-4 and/or IL-13
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
JP5068931B2 (ja) *	2002-07-12	2012-11-07	ザジョンズホプキンスユニバーシティー	独自のクローン形質のリンパ球受容体に結合する試薬および方法
MXPA05000655A (es)	2002-07-15	2006-02-22	Harvard College	Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
US20040110681A1 (en) *	2002-08-08	2004-06-10	Xiao-Min Fan	Method to identify targeting molecules
AU2003259995B2 (en)	2002-08-28	2009-07-02	Immunex Corporation	Compositions and methods for treating cardiovascular disease
DE10251463A1 (de) *	2002-11-05	2004-05-19	BSH Bosch und Siemens Hausgeräte GmbH	Elektrisch angetriebene Pumpe
US20050054054A1 (en) *	2002-11-12	2005-03-10	Foss Francine M.	Interleukin-7 molecules with altered biological properties
BRPI0317376B8 (pt) *	2002-12-17	2021-05-25	Merck Patent Gmbh	proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
US20110223168A1 (en) *	2002-12-27	2011-09-15	Greg Winter	Ligand that has binding specificity for il-4 and/or il-13
EP1578801A2 (en) *	2002-12-27	2005-09-28	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7700100B2 (en) *	2003-01-13	2010-04-20	Macrogenics, Inc.	FcγRIIB fusion proteins and compositions thereof
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060234340A1 (en) *	2003-02-06	2006-10-19	Novozymes A/S	Human heavy chain antibody expression in flamentous fungi
US20050096264A1 (en) *	2003-02-25	2005-05-05	Macdonald Lynn	Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones
CN102225194B (zh)	2003-03-12	2014-07-16	健泰科生物技术公司	Bv8和/或EG-VEGF促进造血的用途
WO2004084816A2 (en) *	2003-03-21	2004-10-07	Progenics Pharmaceuticals, Inc.	IMPROVED CD4-IgG2 FORMULATIONS
JP2007525438A (ja) *	2003-03-24	2007-09-06	ザイモジェネティクス，インコーポレイテッド	抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
EP1606318B1 (en) *	2003-03-26	2009-08-05	Apogenix GmbH	Improved fc fusion proteins
WO2004100882A2 (en) *	2003-05-06	2004-11-25	Syntonix Pharmaceuticals, Inc.	Inhibition of drug binding to serum albumin
DK2298347T3 (en) †	2003-05-06	2016-01-11	Biogen Hemophilia Inc	COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
US7348004B2 (en)	2003-05-06	2008-03-25	Syntonix Pharmaceuticals, Inc.	Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
WO2005000283A2 (en)	2003-05-13	2005-01-06	Depuy Spine, Inc.	A method of treating degenerative disc disease
US7344716B2 (en) *	2003-05-13	2008-03-18	Depuy Spine, Inc.	Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20040229878A1 (en) *	2003-05-13	2004-11-18	Depuy Spine, Inc.	Transdiscal administration of specific inhibitors of P38 kinase
US7553827B2 (en) *	2003-08-13	2009-06-30	Depuy Spine, Inc.	Transdiscal administration of cycline compounds
US8273347B2 (en)	2003-05-13	2012-09-25	Depuy Spine, Inc.	Autologous treatment of degenerated disc with cells
PL1622939T3 (pl) *	2003-05-13	2012-08-31	Merck Serono Sa	Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
US7429378B2 (en) *	2003-05-13	2008-09-30	Depuy Spine, Inc.	Transdiscal administration of high affinity anti-MMP inhibitors
US7435808B2 (en) *	2003-06-25	2008-10-14	Bristol-Myers Squibb Company	Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
AU2004220325B2 (en) *	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
US7569215B2 (en) *	2003-07-18	2009-08-04	Massachusetts Institute Of Technology	Mutant interleukin-2 (IL-2) polypeptides
US8361467B2 (en) *	2003-07-30	2013-01-29	Depuy Spine, Inc.	Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
JP2007504144A (ja)	2003-08-26	2007-03-01	ザリージェンツオブザユニバーシティーオブコロラドアボディーコーポレイト	セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
US20050069521A1 (en) *	2003-08-28	2005-03-31	Emd Lexigen Research Center Corp.	Enhancing the circulating half-life of interleukin-2 proteins
UA89481C2 (uk) *	2003-09-30	2010-02-10	Центокор, Инк.	Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US20070274988A1 (en) *	2003-10-10	2007-11-29	Five Prime Therapeautics, Inc.	Kiaa0779, Splice Variants Thereof, and Methods of Their Use
US20050239700A1 (en) *	2003-10-14	2005-10-27	Biogen Idec Inc.	Treatment of cancer using antibodies to LRRC15
US8129506B2 (en) *	2003-10-24	2012-03-06	Genzyme Corporation	Modulation of the interaction of MUC1 with MUC1 ligands
AU2004290070A1 (en)	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
ES2426169T3 (es) *	2003-11-13	2013-10-21	Hanmi Science Co., Ltd.	Composición farmacéutica que comprende una región Fc de inmunoglobulina como portador
US8110665B2 (en)	2003-11-13	2012-02-07	Hanmi Holdings Co., Ltd.	Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8895540B2 (en)	2003-11-26	2014-11-25	DePuy Synthes Products, LLC	Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ATE393169T1 (de)	2003-12-30	2008-05-15	Merck Patent Gmbh	Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
KR20060124656A (ko) *	2003-12-31	2006-12-05	메르크 파텐트 게엠베하	개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
DE602005016773D1 (de) *	2004-01-22	2009-11-05	Merck Patent Gmbh	Antikrebs-antikörper mit reduzierter komplementfixierung
BRPI0507404A (pt) *	2004-02-06	2007-06-26	Astellas Us Llc	método de tratamento de um indivìduo que tem psorìase e kit
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20100028995A1 (en) *	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
AU2005231359A1 (en) *	2004-03-31	2005-10-20	Centocor, Inc.	Human GLP-1 mimetibodies, compositions, methods and uses
EP1747291A2 (en) *	2004-05-04	2007-01-31	Genaissance Pharmaceuticals, Inc.	Haplotype markers and methods of using the same to determine response to treatment
CA2565259A1 (en) *	2004-05-07	2005-12-08	Astellas Us Llc	Soluble lfa-3 polypeptide for treating viral disorders
US20060063208A1 (en) *	2004-08-02	2006-03-23	Woolf Clifford J	DRG11-responsive (DRAGON) gene and uses thereof
US7393662B2 (en) *	2004-09-03	2008-07-01	Centocor, Inc.	Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
ATE470454T1 (de) *	2004-09-13	2010-06-15	Genzyme Corp	Multimere konstrukte
JP5017116B2 (ja) *	2004-09-24	2012-09-05	アムジエン・インコーポレーテツド	修飾Ｆｃ分子
RS52539B (en) *	2004-10-21	2013-04-30	Genentech Inc.	METHOD FOR TREATMENT OF INTRAOCULAR NEOVASCULAR DISEASES
KR101238684B1 (ko)	2004-10-22	2013-03-04	지모제넥틱스, 인코포레이티드	항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에서의사용방법
US20090311259A1 (en) *	2004-11-17	2009-12-17	Victoria Smith	Compositions and Methods for Treatment of Tumor of Hematopoietic Origin
CA2591297C (en) *	2004-12-09	2015-01-13	Stephen D. Gillies	Il-7 variants with reduced immunogenicity
CN100515491C (zh) *	2005-01-04	2009-07-22	健能隆医药技术（上海）有限公司	白介素-22的医药用途
EP2311880A3 (en)	2005-01-05	2011-07-27	Biogen Idec MA Inc.	Cripto binding molecules
AU2006208241B2 (en)	2005-01-25	2011-08-04	Five Prime Therapeutics, Inc.	Compositions and methods for treating cardiac conditions
US20090155267A1 (en) *	2005-02-09	2009-06-18	Apollo Life Sciences Limited	Molecule and chimeric molecules thereof
KR100754667B1 (ko)	2005-04-08	2007-09-03	한미약품 주식회사	비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US9284375B2 (en) *	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9963510B2 (en) *	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP1868650B1 (en)	2005-04-15	2018-10-03	MacroGenics, Inc.	Covalent diabodies and uses thereof
JO3058B1 (ar)	2005-04-29	2017-03-15	Applied Molecular Evolution Inc	الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US7531637B2 (en)	2005-05-06	2009-05-12	Zymogenetics, Inc.	IL-31 monoclonal antibodies
WO2006138737A2 (en) *	2005-06-17	2006-12-28	Elan Pharma International Limited	Methods of purifying anti a beta antibodies
EP3501537A1 (en)	2005-06-30	2019-06-26	Janssen Biotech, Inc.	Anti-il23 antibodies, compositions, methods and uses
DK1904104T3 (da)	2005-07-08	2013-11-11	Biogen Idec Inc	SP35-antistoffer og anvendelser heraf
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
AU2006280004A1 (en) *	2005-08-12	2007-02-22	Schering Corporation	MCP1 fusions
KR20080050591A (ko)	2005-09-01	2008-06-09	아레스 트레이딩 에스.에이.	시신경염 치료
US20070104689A1 (en) *	2005-09-27	2007-05-10	Merck Patent Gmbh	Compositions and methods for treating tumors presenting survivin antigens
ZA200804078B (en) *	2005-10-13	2009-09-30	Virexx Medical Corp	Chimeric hepatitis C virus antigens for eliciting an immune response
TW200722436A (en) *	2005-10-21	2007-06-16	Hoffmann La Roche	A peptide-immunoglobulin-conjugate
US20070161081A1 (en) *	2005-11-10	2007-07-12	Receptor Biologix, Inc.	Hepatocyte growth factor intron fusion proteins
UA94244C2 (ru)	2005-11-14	2011-04-26	Ринат Нейросаенз Корп.	Анти-cgrp антагонистическое антитело и фармацевтическая композиция, которая его включает
EA200801170A1 (ru) *	2005-12-01	2008-12-30	Домантис Лимитед	Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
WO2007064911A1 (en) *	2005-12-02	2007-06-07	Biogen Idec Inc.	Anti-mouse cd20 antibodies and uses thereof
US20070161546A1 (en) *	2005-12-15	2007-07-12	Colm King	Methods and compositions for treatment of cancer
JP2009521503A (ja) *	2005-12-22	2009-06-04	ディー・エイチ・ワイ・アンド・カンパニー・リミテッド	インターロイキン−２２結合タンパク質に対する抗体と、代謝性疾患の処置のためのその使用
RS60616B1 (sr)	2005-12-29	2020-09-30	Janssen Biotech Inc	Humana anti-il-23 antitela, kompozicije, postupci i upotrebe
PT1966238E (pt) *	2005-12-30	2012-07-31	Merck Patent Gmbh	Uso de hsp70 como um regulador de atividade enzimática
CA2635623C (en) *	2005-12-30	2015-02-17	Michael Super	Anti-cd19 antibodies with reduced immunogenicity
KR101345586B1 (ko)	2006-01-10	2013-12-31	지모제넥틱스, 인코포레이티드	Ｉｌ-31 길항제를 사용한 신경세포 조직의 통증 및 염증 치료 방법
US7625564B2 (en)	2006-01-27	2009-12-01	Novagen Holding Corporation	Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP1991577A2 (en)	2006-01-31	2008-11-19	Parkinson, John F.	Modulation of mdl-1 activity for treatment of inflammatory disease
GB0604187D0 (en) *	2006-03-02	2006-04-12	Fusion Antibodies Ltd	Peptide and uses thereof
CA2648053A1 (en) *	2006-03-31	2007-10-11	Centocor, Inc.	Binding partners with immunoglobulin domains modified to have extended half-life
JP2009537605A (ja)	2006-05-24	2009-10-29	メルクセローノソシエテアノニム	多発性硬化症を治療するためのクラドリビン・レジメン
KR20090031897A (ko) *	2006-06-12	2009-03-30	리셉터 바이오로직스 인크	전-세포 표면 수용체-특이적 치료제
JP2009544574A (ja) *	2006-06-22	2009-12-17	バクシネックスインコーポレーティッド	癌を処置するための抗ｃ３５抗体
WO2008036449A2 (en) *	2006-06-29	2008-03-27	The Regents Of The University Of California	Chemical antibodies for immunotherapy and imaging
EP2851064A3 (en)	2006-07-11	2015-08-05	Roy C. Levitt	Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US20080014285A1 (en) *	2006-07-13	2008-01-17	Di Mauro Thomas M	Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
US8940683B2 (en)	2006-08-10	2015-01-27	Roy C. Levitt	Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
JP2010500876A (ja)	2006-08-18	2010-01-14	アブリンクスエン．ヴェー．	Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2067041A2 (en)	2006-10-03	2009-06-10	Biogen Idec MA, Inc.	Biomarkers and assays for the treatment of cancer
NZ576445A (en)	2006-11-02	2012-03-30	Daniel J Capon	Hybrid immunoglobulins with moving parts
PE20081250A1 (es)	2006-11-28	2008-10-07	Centelion	FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
CN102603893A (zh)	2007-01-05	2012-07-25	苏黎世大学	提供疾患特异性结合分子和靶的方法
ES2673153T3 (es)	2007-01-09	2018-06-20	Biogen Ma Inc.	Anticuerpos Sp35 y usos de los mismos
CA2678493A1 (en)	2007-02-23	2008-08-28	The Trustees Of Columbia University In The City Of New York	Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
EP2134834B1 (en) *	2007-03-07	2013-04-17	GlycoFi, Inc.	Production of glycoproteins with modified fucosylation
EP2388266B1 (en)	2007-05-11	2014-04-23	Altor BioScience Corporation	Fusion molecules and IL-15 variants
US7906149B2 (en) *	2007-05-25	2011-03-15	Boval Company, L.P.	Method for treating allergic dermatitis
EP2164508B1 (en) *	2007-06-04	2014-01-08	Rappaport Family Institute for Research in the Medical Sciences	Agents for the treatment of inflammatory diseases and methods of using same
KR20100040840A (ko) *	2007-06-06	2010-04-21	도만티스 리미티드	폴리펩티드，항체 가변 도메인 및 길항제
US8067548B2 (en) *	2007-07-26	2011-11-29	Novagen Holding Corporation	Fusion proteins having mutated immunoglobulin hinge region
GB0717337D0 (en) *	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
EP2573112A1 (en)	2007-10-11	2013-03-27	The Hospital For Sick Children	Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
KR20100082775A (ko) *	2007-10-16	2010-07-19	심포젠 에이/에스	최적화된 ｈｅｒ1 및 ｈｅｒ3 멀티머를 포함하는 조성물 및 그것의 사용 방법
CA2703263C (en) *	2007-11-01	2014-03-18	Perseid Therapeutics Llc	Immunosuppressive polypeptides and nucleic acids
WO2009061853A2 (en) *	2007-11-05	2009-05-14	Massachusetts Institute Of Technology	Mutant interleukin-2 (il-2) polypeptides
KR20100090683A (ko) *	2007-11-09	2010-08-16	제넨테크, 인크.	액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
HUE046564T2 (hu)	2007-11-21	2020-03-30	Univ Oregon Health & Science	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
US20090312249A1 (en) *	2007-12-06	2009-12-17	Korea Advanced Institute Of Science And Technology	TLR4 decoy receptor protein
ES2570853T3 (es) *	2007-12-07	2016-05-20	Zymogenetics Inc	Moléculas de anticuerpo humanizadas específicas para IL-31
US20090162351A1 (en) *	2007-12-21	2009-06-25	Depuy Spine, Inc.	Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) *	2007-12-21	2015-03-24	Depuy Mitek, Inc.	Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
ES2689322T3 (es)	2008-03-04	2018-11-13	Teva Pharmaceuticals International Gmbh	Métodos para tratar el dolor crónico
US8669349B2 (en)	2008-04-02	2014-03-11	Macrogenics, Inc.	BCR-complex-specific antibodies and methods of using same
KR20110021832A (ko) *	2008-05-02	2011-03-04	노파르티스 아게	개선된 피브로넥틴기재 결합 분자 및 그의 용도
HUE030092T2 (en)	2008-05-06	2017-05-29	Genentech Inc	Affinity CRIg variants
ES2675730T3 (es) *	2008-06-04	2018-07-12	Macrogenics, Inc.	Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
AU2009269099B2 (en)	2008-07-09	2016-03-10	Biogen Ma Inc.	Compositions comprising antibodies to LINGO or fragments thereof
CN102112493B (zh)	2008-07-23	2015-04-01	韩美科学株式会社	包含具有三个官能性末端的非肽基聚合物的多肽复合物
EP2370466B8 (en)	2008-12-19	2015-06-24	Biogen Idec International Neuroscience GmbH	Human anti-alpha-synuclein autoantibodies
US20100159485A1 (en) *	2008-12-19	2010-06-24	Centre For Dna Fingerprinting And Diagnostics	Detection of mycobacterium tuberculosis
AU2009334498A1 (en)	2008-12-31	2011-07-21	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
EP2411412B1 (en)	2009-03-24	2015-05-27	Teva Biopharmaceuticals USA, Inc.	Humanized antibodies against light and uses thereof
UA105384C2 (ru)	2009-04-01	2014-05-12	Дженентек, Инк.	Лечение нарушений, связанных с инсулинорезистентностью
CA2758191C (en)	2009-04-10	2015-06-30	Ablynx N.V.	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US10618964B2 (en)	2009-04-10	2020-04-14	Ablynx N.V.	Nanobody against IL-6R
KR20120030383A (ko)	2009-04-22	2012-03-28	메르크 파텐트 게엠베하	변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
CN102439044B (zh)	2009-04-22	2014-08-13	阿特根公司	通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
SG175417A1 (en)	2009-05-08	2011-12-29	Vaccinex Inc	Anti-cd100 antibodies and methods for using the same
EP4311863A3 (en)	2009-05-15	2024-04-10	University Health Network	Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
CA2765188A1 (en)	2009-06-15	2010-12-23	Biokine Therapeutics Ltd.	Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
US20110039300A1 (en)	2009-08-10	2011-02-17	Robert Bayer	Antibodies with enhanced adcc functions
WO2011019622A1 (en)	2009-08-14	2011-02-17	Genentech, Inc.	Cell culture methods to make antibodies with enhanced adcc function
IN2012DN02521A (nl)	2009-08-28	2015-08-28	Rinat Neuroscience Corp
US9096877B2 (en)	2009-10-07	2015-08-04	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
US20110165122A1 (en) *	2009-11-10	2011-07-07	The Regents Of The University Of California	Method for targeted and sustained antiviral therapy
US20120269830A1 (en)	2009-12-07	2012-10-25	Lawrence Horowitz	Conjugates with improved pharmacokinetic properties
EP2516467A2 (en)	2009-12-23	2012-10-31	Emergent Product Development Seattle, LLC	Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US8637637B2 (en)	2010-01-12	2014-01-28	Bill Nai-Chau Sun	Fc fusion proteins of human growth hormone
SI2523688T1 (en)	2010-01-15	2018-03-30	Kirin-Amgen, Inc.	Formulation of antibodies and therapeutic regimes
US8895700B2 (en)	2010-02-18	2014-11-25	Janssen Biotech, Inc.	Monkey homolog of human interferon omega
ES2895480T3 (es)	2010-03-04	2022-02-21	Macrogenics Inc	Anticuerpos reactivos con B7-H3, fragmentos inmunológicamente activos de los mismos y usos de los mismos
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
AU2011230537C1 (en)	2010-03-26	2018-08-02	Trustees Of Dartmouth College	Vista regulatory T cell mediator protein, vista binding agents and use thereof
US20110243942A1 (en) *	2010-04-02	2011-10-06	Athena Discovery, Inc.	Relaxin-fusion proteins with extended in vivo half-lives
WO2011130533A1 (en)	2010-04-16	2011-10-20	Centocor Ortho Biotech Inc.	Engineered plant cysteine proteases and their uses
US8524217B2 (en)	2010-05-11	2013-09-03	Merck Sharp & Dohme Corp.	MCP1-Ig fusion variants
EP2582387A2 (en)	2010-06-17	2013-04-24	The United States Of America As Represented By The Secretary, National Institutes Of Health	Compositions and methods for treating inflammatory conditions
EP3508573A1 (en)	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
BR112013002533A2 (pt)	2010-08-02	2021-09-08	Macrogenics, Inc	Polipeptídeo de ligação de proteína sérica e diacorpo complexado ao polipeptídeo de ligação de proteína sérica
DK2601214T3 (en)	2010-08-06	2018-02-05	Genzyme Corp	VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
DK2611832T3 (en)	2010-09-02	2018-02-26	Vaccinex Inc	ANTI-CXCL13 ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP3851459B1 (en)	2010-09-21	2024-05-01	Altor BioScience, LLC	Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en)	2010-09-21	2021-07-06	Immunity Bio, Inc.	Superkine
EP3050899B1 (en)	2010-09-27	2019-09-04	Janssen Biotech, Inc.	Antibodies binding human collagen ii
BR112013008765B8 (pt)	2010-10-11	2023-05-02	Biogen Idec Int Neuroscience Gmbh	Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
US8883134B2 (en) *	2010-10-20	2014-11-11	Handok Pharmaceuticals, Inc.	Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
US20120201821A1 (en)	2010-10-25	2012-08-09	Gonzalez Jr Lino	Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
SG189981A1 (en) *	2010-11-08	2013-06-28	Novartis Ag	Cxcr2 binding polypeptides
US9283271B2 (en)	2010-12-17	2016-03-15	Neurimmune Holding Ag	Human anti-SOD1 antibodies
DK2709663T3 (da)	2011-05-20	2019-05-20	Alderbio Holdings Llc	Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
DK2709662T3 (da)	2011-05-20	2019-11-04	Alderbio Holdings Llc	Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
AR086516A1 (es)	2011-05-20	2013-12-18	Alderbio Holdings Llc	Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso
KR102030531B1 (ko)	2011-05-21	2019-10-10	마크로제닉스, 인크.	탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
TWI560200B (en)	2011-05-25	2016-12-01	Innate Pharma Sa	Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
AU2012272790B2 (en)	2011-06-23	2016-10-06	Biogen International Neuroscience Gmbh	Anti-alpha synuclein binding molecules
KR20200044138A (ko)	2011-06-24	2020-04-28	더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트	알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
KR20140039257A (ko) *	2011-07-08	2014-04-01	바이엘 인텔렉쳐 프로퍼티 게엠베하	릴랙신을 방출하는 융합 단백질 및 이의 용도
US9738707B2 (en)	2011-07-15	2017-08-22	Biogen Ma Inc.	Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en)	2011-07-22	2013-01-31	Amgen Inc.	Il-17 receptor a is required for il-17c biology
AU2012311443B2 (en) *	2011-09-23	2016-12-01	Ablynx Nv	Prolonged inhibition of interleukin-6 mediated signaling
US11951157B2 (en)	2011-10-11	2024-04-09	Universitat Zurich	Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
WO2013053775A1 (en) *	2011-10-11	2013-04-18	Universität Zürich Prorektorat Mnw	Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
WO2013063155A2 (en)	2011-10-24	2013-05-02	Halozyme, Inc.	Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
JP2015504675A (ja)	2012-01-10	2015-02-16	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
NZ629828A (en)	2012-03-02	2017-05-26	Vaccinex Inc	Methods for the treatment of b cell-mediated inflammatory diseases
US9289507B2 (en)	2012-05-17	2016-03-22	Extend Biosciences, Inc.	Carriers for improved drug delivery
DK2852610T3 (en)	2012-05-23	2018-09-03	Glykos Finland Oy	PRODUCTION OF FUCOSYLED GLYCOPROTEIN
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh)	2012-06-22	2022-10-04	达特茅斯大学理事会	新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
WO2014011775A1 (en)	2012-07-10	2014-01-16	The Trustees Of The University Of Pennsylvania	Biomaterials for enhanced implant-host integration
ES2771324T3 (es)	2012-08-03	2020-07-06	Dana Farber Cancer Inst Inc	Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
CA2881966C (en)	2012-08-24	2020-10-06	The Regents Of The University Of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP2892558B1 (en)	2012-09-07	2019-04-10	The Trustees Of Dartmouth College	Vista modulators for diagnosis and treatment of cancer
US9278124B2 (en)	2012-10-16	2016-03-08	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
ES2914814T3 (es)	2012-12-17	2022-06-16	Pf Argentum Ip Holdings Llc	Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
US20150320799A1 (en)	2012-12-20	2015-11-12	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
KR102234324B1 (ko)	2012-12-21	2021-03-31	바이오젠 엠에이 인코포레이티드	인간 항-타우 항체
EP2938631B1 (en)	2012-12-31	2018-12-19	Neurimmune Holding AG	Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2014137355A1 (en)	2013-03-08	2014-09-12	Vaccinex, Inc.	Anti-cxcl13 antibodies and associated epitope sequences
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PT2968520T (pt)	2013-03-14	2021-08-19	Macrogenics Inc	Moléculas biespecíficas que são imunorreativas com células efetoras imunitárias que expressam um recetor de ativação
CN114717206A (zh)	2013-03-15	2022-07-08	Atyr 医药公司	组氨酰-trna合成酶-fc缀合物
SG10201808523RA (en)	2013-03-15	2018-11-29	Genentech Inc	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
SG11201505926VA (en)	2013-03-15	2015-09-29	Biogen Ma Inc	Factor ix polypeptide formulations
CA2911514A1 (en)	2013-05-06	2014-11-13	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
EP3293275B1 (en)	2013-06-06	2021-08-04	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
AR096891A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3049442A4 (en)	2013-09-26	2017-06-28	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
US20160297875A1 (en)	2013-12-07	2016-10-13	Case Western Reserve University	Compositions and methods of treating thrombosis
US11708411B2 (en)	2013-12-20	2023-07-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SI3712174T1 (sl)	2013-12-24	2022-06-30	Janssen Pharmaceutica Nv	Protitelesa in delci proti VISTA
AU2015206603B9 (en)	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US10047133B2 (en) *	2014-01-22	2018-08-14	Antagonis Biotherapeutics Gmbh	Glycosaminoglycan-antagonising fusion proteins and methods of using same
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20200126018A (ko)	2014-03-21	2020-11-05	테바 파마슈티컬스 인터내셔널 게엠베하	칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
SG11201607881SA (en)	2014-03-31	2016-10-28	Kirin Amgen Inc	Methods of treating nail and scalp psoriasis
MX389695B (es)	2014-06-11	2025-03-20	Kathy A Green	Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
JP6842926B2 (ja)	2014-06-30	2021-03-17	アルター・バイオサイエンス・コーポレーション	Ｉｌ−１５ベース分子及びその使用方法
EP3172333B1 (en)	2014-07-21	2020-05-13	Glykos Finland Oy	Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
WO2016016278A2 (en)	2014-07-29	2016-02-04	Neurimmune Holding Ag	Human-derived anti-huntingtin (htt) antibodies and uses thereof
CN107001417B (zh)	2014-08-04	2021-04-30	卡斯西部储备大学	靶向肽及其使用方法
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016054101A1 (en)	2014-09-29	2016-04-07	Duke University	Bispecific molecules comprising an hiv-1 envelope targeting arm
JP6637971B2 (ja)	2014-09-30	2020-01-29	ニューリミューンホールディングエイジー	ヒト由来の抗ジペプチドリピート（ｄｐｒ）抗体
CN107074954A (zh)	2014-10-21	2017-08-18	埃博灵克斯股份有限公司	Il‑6r相关疾病的治疗
US9616109B2 (en)	2014-10-22	2017-04-11	Extend Biosciences, Inc.	Insulin vitamin D conjugates
US9789197B2 (en)	2014-10-22	2017-10-17	Extend Biosciences, Inc.	RNAi vitamin D conjugates
WO2016065042A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Therapeutic vitamin d conjugates
MX2017007136A (es)	2014-12-05	2017-12-04	Immunext Inc	Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
WO2016094273A1 (en)	2014-12-08	2016-06-16	Dana-Farber Cancer Institute, Inc.	Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
JP2018506275A (ja)	2015-01-28	2018-03-08	ジェネンテック，インコーポレイテッド	多発性硬化症の遺伝子発現マーカー及び治療
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11820807B2 (en)	2015-06-12	2023-11-21	Ubi Pharma Inc	Immunoglobulin fusion proteins and uses thereof
DK3313882T3 (da)	2015-06-24	2020-05-11	Janssen Pharmaceutica Nv	Anti-VISTA antistoffer og fragmenter
BR112018001353A2 (pt)	2015-08-07	2018-09-11	Alexo Therapeutics, Inc.	construtos tendo um domínio de sirp-alfa ou variante do mesmo
JP7020687B2 (ja)	2015-09-15	2022-02-16	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用
WO2017062757A1 (en)	2015-10-08	2017-04-13	Massachusetts Institute Of Technology	In situ expansion of engineered devices for regeneration
EP3362074B1 (en)	2015-10-16	2023-08-09	President and Fellows of Harvard College	Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
KR102828755B1 (ko)	2015-12-17	2025-07-03	바이오카인 테라퓨틱스 리미티드	케모카인 활성 및/또는 암세포 성장 억제용 저분자
EP3390378B1 (en)	2015-12-17	2022-03-30	AlonBio Ltd.	Small molecules against cancer
EP3397274A1 (en)	2015-12-31	2018-11-07	The Regents of the University of Colorado, a body corporate	Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
JP2019509993A (ja)	2016-02-12	2019-04-11	ヤンセンファーマシューティカエヌブイ	抗ｖｉｓｔａ（ｂ７ｈ５）抗体
KR102802736B1 (ko)	2016-03-10	2025-05-02	비엘라 바이오, 인크.	Ilt7 결합 분자 및 이의 사용 방법
US12144850B2 (en)	2016-04-08	2024-11-19	Purdue Research Foundation	Methods and compositions for car T cell therapy
GEP20227398B (en)	2016-04-15	2022-07-25	Macrogenics Inc	Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
CR20180537A (es)	2016-04-15	2019-03-04	Immunext Inc	Anticuerpos vista antihumanos y su uso
WO2017205726A1 (en)	2016-05-27	2017-11-30	Altor Bioscience Corporation	Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
KR20190066607A (ko)	2016-09-23	2019-06-13	테바 파마슈티컬스 인터내셔널 게엠베하	불응성 편두통의 치료
MX2019004681A (es)	2016-10-21	2019-10-07	Altor Bioscience Corp	Moleculas basadas en il-15 multimericas.
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3052095A1 (en)	2017-01-30	2018-08-02	Janssen Biotech, Inc.	Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
MA47442A (fr)	2017-02-07	2019-12-18	Janssen Biotech Inc	Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
US11649288B2 (en)	2017-02-07	2023-05-16	Seattle Children's Hospital	Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
AU2018229278A1 (en)	2017-02-28	2019-10-17	Sanofi	Therapeutic RNA
ES3010559T3 (en)	2017-02-28	2025-04-03	Endocyte Inc	Compositions and methods for car t cell therapy
CA3216726A1 (en)	2017-03-06	2018-09-13	Altor Bioscience Corporation	Il-15-based fusions to il-12 and il-18
US20190048055A1 (en)	2017-03-31	2019-02-14	Altor Bioscience Corporation	Alt-803 in combination with anti-cd38 antibody for cancer therapies
US11767520B2 (en)	2017-04-20	2023-09-26	Atyr Pharma, Inc.	Compositions and methods for treating lung inflammation
CA3061963A1 (en)	2017-05-05	2018-11-08	Vaccinex, Inc.	Human anti-semaphorin 4d antibody
JP2020533971A (ja)	2017-08-28	2020-11-26	アルター・バイオサイエンス・コーポレーション	Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
WO2019101960A1 (en)	2017-11-24	2019-05-31	Merck Patent Gmbh	Cladribine regimen for use intreating progressive forms of multiple sclerosis
EP3743082A4 (en)	2018-01-22	2021-11-03	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	PROCESSES FOR USING T CAR CELLS
TWI835772B (zh)	2018-01-26	2024-03-21	美商建南德克公司	Il-22fc融合蛋白及使用方法
EP3743088B1 (en)	2018-01-26	2022-10-12	F. Hoffmann-La Roche AG	Il-22 fc compositions and methods of use
SG11202007426XA (en)	2018-02-06	2020-09-29	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
MA51907A (fr)	2018-02-21	2021-05-26	Hoffmann La Roche	Posologie pour un traitement avec des protéines de fusion il-22 fc
AU2019225174A1 (en)	2018-02-23	2020-09-03	Endocyte, Inc.	Sequencing method for CAR T cell therapy
EP3759125A4 (en)	2018-02-28	2021-12-08	Dana-Farber Cancer Institute, Inc.	CANCER TREATMENT METHODS USING COMBINATIONS OF ANTI-BTNL2 BLOCKING AGENTS AND IMMUNE CHECKPOINTS
CA3089333C (en)	2018-03-26	2023-10-10	Altor Bioscience Llc	Anti-pdl1, il-15 and tgf-beta receptor combination molecules
CA3091859A1 (en)	2018-04-06	2019-10-24	Dana-Farber Cancer Institute, Inc.	Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
JP7485368B2 (ja)	2018-04-26	2024-05-16	グッドティーセルズ、インコーポレイテッド	新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
KR20210033995A (ko)	2018-06-22	2021-03-29	큐진 인크.	인터루킨-2 변이체 및 이의 사용 방법
JP7340862B2 (ja) *	2018-06-28	2023-09-08	国立大学法人岡山大学	好中球貪食能増強剤
WO2020022782A1 (ko)	2018-07-24	2020-01-30	주식회사 굳티셀	면역 관련 질환의 예방 또는 치료용 조성물
CN110964116A (zh)	2018-09-26	2020-04-07	北京辅仁瑞辉生物医药研究院有限公司	GLP1-Fc融合蛋白及其缀合物
CR20210373A (es)	2019-01-08	2021-08-19	H Lundbeck As	Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
AU2020208828A1 (en)	2019-01-15	2021-08-05	Janssen Biotech, Inc.	Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EA202192038A1 (ru)	2019-01-23	2021-10-05	Янссен Байотек, Инк.	Композиции антител к фно для применения в способах лечения псориатического артрита
MX2021009662A (es)	2019-02-13	2021-09-08	Brigham & Womens Hospital Inc	Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
JP2022525179A (ja)	2019-03-14	2022-05-11	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための産生方法
US12129292B2 (en)	2019-03-14	2024-10-29	Janssen Biotech, Inc.	Anti-tumor necrosis factor (TNF) antibodies and compositions thereof
WO2020183270A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Methods for producing anti-tnf antibody compositions
EP3962529A4 (en)	2019-04-30	2023-11-01	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
BR112021022775A2 (pt)	2019-05-15	2022-02-01	Alonbio Ltd	Moléculas pequenas para tratamento do câncer, inibição da atividade da quimiocina e/ou indução da morte celular
US12221481B2 (en)	2019-05-21	2025-02-11	Novartis Ag	CD19 binding molecules and uses thereof
CN113874073A (zh)	2019-05-23	2021-12-31	詹森生物科技公司	用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
EP3976099A1 (en)	2019-05-31	2022-04-06	ALX Oncology Inc.	Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
BR112021024401A2 (pt)	2019-06-03	2022-04-19	Janssen Biotech Inc	Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
KR20220029593A (ko)	2019-06-03	2022-03-08	얀센 바이오테크 인코포레이티드	건선성 관절염의 치료를 위한 항-tnf 항체 조성물, 및 방법
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
KR20220114063A (ko)	2019-12-13	2022-08-17	큐진 인크.	신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도
US20230075965A1 (en)	2020-01-24	2023-03-09	Constantine S. Mitsiades	Uses of biomarkers for improving immunotherapy
CA3173521A1 (en)	2020-02-28	2021-09-02	The Brigham And Women's Hospital, Inc.	Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
TWI888497B (zh)	2020-03-05	2025-07-01	美商迪亞醫藥美國公司	烏司他丁多肽
BR102020007149A8 (pt)	2020-04-06	2023-09-26	H Lundbeck As	Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
JPWO2021230233A1 (nl) *	2020-05-14	2021-11-18
CN115768466A (zh)	2020-05-21	2023-03-07	詹森生物科技公司	用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
EP4337190A1 (en)	2021-05-13	2024-03-20	ALX Oncology Inc.	Combination therapies for treating cancer
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN117957251A (zh)	2021-07-09	2024-04-30	詹森生物科技公司	用于制备抗tnf抗体组合物的制造方法
AU2022306144A1 (en)	2021-07-09	2024-02-22	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
WO2023097119A2 (en)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
WO2023168426A1 (en)	2022-03-03	2023-09-07	Enosi Therapeutics Corporation	Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
EP4490202A1 (en)	2022-03-11	2025-01-15	University of Rochester	Cyclopeptibodies and uses thereof
AU2023264772A1 (en)	2022-05-02	2024-10-24	Novo Nordisk A/S	Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
AU2023353057A1 (en)	2022-09-30	2025-05-01	Extend Biosciences, Inc.	Long-acting parathyroid hormone
WO2024186690A2 (en)	2023-03-03	2024-09-12	Enosi Therapeutics Corporation	Oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
DE2247163A1 (de)	1972-09-26	1974-03-28	Merck Patent Gmbh	Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
GB1479268A (en)	1973-07-05	1977-07-13	Beecham Group Ltd	Pharmaceutical compositions
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
ATE12348T1 (de)	1980-11-10	1985-04-15	Gersonde Klaus Prof Dr	Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja)	1981-07-16	1983-01-22	Niles Parts Co Ltd	方位検出表示回路
NZ201705A (en)	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
US4444878A (en)	1981-12-21	1984-04-24	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
JPS59125144A (ja)	1982-12-30	1984-07-19	ソニー株式会社	デイジタル信号伝送方法
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0375654B1 (fr)	1983-04-20	1994-06-01	Youri Agabekov	Assemblage d'un adaptateur de fixation d'une lampe d'éclairage à contact fourchette et rampe d'alimentation électrique
EP0142541B1 (en)	1983-05-09	1987-07-08	THE GENERAL ELECTRIC COMPANY, p.l.c.	Cathode ray tube display device
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
EP0173494A3 (en) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US4745055A (en)	1985-05-07	1988-05-17	California Biotechnology Inc.	Fused protein for enzyme immunoassay system
DE3523701A1 (de) *	1985-07-03	1987-01-08	Bayer Ag	Verfahren zur herstellung von proteinen und polypeptiden
DE3712985A1 (de) *	1987-04-16	1988-11-03	Hoechst Ag	Bifunktionelle proteine
ATE143052T1 (de)	1986-07-07	1996-10-15	Centocor Inc	Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
NO873164L (no)	1986-07-30	1988-02-01	Teijin Ltd	Muse-humane kimaere antistoffer.
GB8623843D0 (en)	1986-10-03	1987-10-21	Airtech Ltd	Detection of unsafe voltages on mobile equipment
GB8626412D0 (en)	1986-11-05	1986-12-03	Clark M R	Antibodies
CA1339445C (en)	1986-11-12	1997-09-09	The General Hospital Corporation	Recombinant hybrid immunoglobulin molecules and method of use
EP0294703B1 (en) *	1987-06-10	1995-05-10	Dana-Farber Cancer Institute, Inc.	Bifunctional antibody constructs and method for selectively destroying cell populations
IL87737A (en)	1987-09-11	1993-08-18	Genentech Inc	Method for culturing polypeptide factor dependent vertebrate recombinant cells
SE459586B (sv) *	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
JP2755395B2 (ja) *	1987-09-23	1998-05-20	ブリストル―マイアーズスクイブコムパニー	Ｈｉｖ感染細胞に殺作用する抗体異種結合体
PT88641B (pt) *	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
GB8725529D0 (en) *	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
US4978745A (en) *	1987-11-23	1990-12-18	Centocor, Inc.	Immunoreactive heterochain antibodies
DE721983T1 (de) *	1988-01-22	2002-07-04	Zymogenetics, Inc.	Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
ZA89430B (en) *	1988-01-22	1989-10-25	Gen Hospital Corp	Cloned genes encoding ig-cd4 fusion proteins and the use thereof
GB8801756D0 (en)	1988-01-27	1988-02-24	Shell Int Research	Copolymer composition
SE8802176D0 (sv) *	1988-06-10	1988-06-10	Kabigen Ab	Fusion protein and its use
EP0355068A3 (en) *	1988-08-19	1991-09-04	The General Hospital Corporation	Recombinant hybrid immunoglobulin molecules and their use
EP0368684B2 (en) *	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
AU638964B2 (en)	1988-12-22	1993-07-15	Genentech Inc.	Method for preparing water soluble polypeptides
CA2010321C (en) *	1989-02-21	2004-04-06	Thomas F. Tedder	Lymphocyte-associated cell surface protein
DE69033983T2 (de) *	1989-03-16	2003-03-20	Center For Blood Research, Inc.	Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
EP0394827A1 (en) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) *	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
IE901736L (en) *	1989-05-17	1990-11-17	Fuller H B Licensing Financ	Polypeptide-antibody conjugate for inhibiting cell adhesion
WO1991000360A1 (en) *	1989-06-29	1991-01-10	Medarex, Inc.	Bispecific reagents for aids therapy
FR2650598B1 (fr) *	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
FI920658A0 (fi) *	1989-08-23	1992-02-14	Gen Hospital Corp	Cd4-polypeptider av icke-maenskliga primater, fusionsproteiner daerav, dna, som kodar foer dessa, samt deras anvaendningar.
DK0765937T3 (da) *	1989-09-20	2003-03-24	Abbott Lab	Fremgangsmåde til fremstilling af fusionsproteiner

1989
- 1989-11-22 US US07/440,625 patent/US5116964A/en not_active Expired - Lifetime
1990
- 1990-11-21 DE DE122008000063C patent/DE122008000063I2/de active Active
- 1990-11-21 AT AT99123412T patent/ATE396735T1/de active
- 1990-11-21 EP EP08005947A patent/EP1970386A2/en not_active Withdrawn
- 1990-11-21 WO PCT/US1990/006849 patent/WO1991008298A2/en active IP Right Grant
- 1990-11-21 DE DE69034253T patent/DE69034253D1/de not_active Expired - Lifetime
- 1990-11-21 DE DE69033705T patent/DE69033705T3/de not_active Expired - Lifetime
- 1990-11-21 CA CA002072642A patent/CA2072642C/en not_active Expired - Lifetime
- 1990-11-21 ES ES99123412T patent/ES2308826T3/es not_active Expired - Lifetime
- 1990-11-21 EP EP91901202A patent/EP0526452B2/en not_active Expired - Lifetime
- 1990-11-21 JP JP3501520A patent/JPH05503009A/ja not_active Withdrawn
- 1990-11-21 DK DK99123412T patent/DK1029870T3/da active
- 1990-11-21 EP EP99123412A patent/EP1029870B1/en not_active Expired - Lifetime
- 1990-11-21 AT AT91901202T patent/ATE199261T1/de not_active IP Right Cessation
- 1990-11-21 ES ES91901202T patent/ES2155819T5/es not_active Expired - Lifetime
- 1990-11-21 DK DK91901202T patent/DK0526452T4/da active
2001
- 2001-05-11 GR GR20010400708T patent/GR3035856T3/el unknown
2002
- 2002-02-04 JP JP2002026825A patent/JP2002325589A/ja not_active Withdrawn
2008
- 2008-11-19 LU LU91498C patent/LU91498I2/xx unknown
- 2008-11-27 NL NL300372C patent/NL300372I1/nl unknown

Also Published As

Publication number	Publication date
EP1029870A2 (en)	2000-08-23
ATE199261T1 (de)	2001-03-15
EP0526452A1 (en)	1993-02-10
DE69033705D1 (de)	2001-03-29
ES2155819T5 (es)	2007-09-16
DK1029870T3 (da)	2008-09-29
CA2072642A1 (en)	1991-05-23
DE69034253D1 (de)	2008-07-10
DE122008000063I1 (de)	2009-02-19
DK0526452T3 (da)	2001-06-18
DE69033705T3 (de)	2007-07-12
DE122008000063I2 (de)	2011-06-16
EP1970386A8 (en)	2009-07-08
EP1029870A3 (en)	2000-12-13
EP1970386A2 (en)	2008-09-17
ATE396735T1 (de)	2008-06-15
ES2308826T3 (es)	2008-12-01
DK0526452T4 (da)	2007-05-07
LU91498I2 (fr)	2009-01-19
WO1991008298A2 (en)	1991-06-13
HK1013298A1 (en)	1999-08-20
WO1991008298A3 (en)	1991-10-17
EP1029870B1 (en)	2008-05-28
EP0526452B2 (en)	2007-01-03
DE69033705T2 (de)	2001-08-02
CA2072642C (en)	2002-07-23
JPH05503009A (ja)	1993-05-27
HK1030222A1 (en)	2001-04-27
JP2002325589A (ja)	2002-11-12
GR3035856T3 (en)	2001-08-31
EP0526452B1 (en)	2001-02-21
US5116964A (en)	1992-05-26
ES2155819T3 (es)	2001-06-01

Publication	Publication Date	Title
NL300372I1 (nl)	2009-02-02	Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
ATE47155T1 (de)	1989-10-15	Monoklonaler antikoerper.
BR8107293A (pt)	1982-08-03	Polipetidio anti-viral dna de duplo cordao veiculo de expressao plasmidico replicavel microorganismo transformado plasmidio processo de formacao do dito dna e do dito polipeptidio composicao farmaceutica e uso do dito polipeptidio
EP0315683A4 (en)	1990-02-05	Dna sequences, recombinant dna molecules and processes for producing lymphocyte function associated antigen-3.
DE3585953D1 (de)	1992-06-04	Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
EP0442961A4 (en)	1992-04-08	Hybrid procoagulant proteins
PH25120A (en)	1991-02-19	Replicable expression vehicle and process of preparation thereof
DE69937899D1 (de)	2008-02-14	Antikörper-serumprotein hybride
DE69535719D1 (de)	2008-04-10	Fas-antigenbindender ligand
DE69334350D1 (de)	2011-04-21	P- Selectin Ligandenprotein
ES552431A0 (es)	1987-09-01	Procedimiento para preparar plasmidos de expresion prhw11 y prhw12
FI863626A7 (fi)	1986-09-09	DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
NO169819C (no)	1992-08-12	Fremgangsmaate for fremstilling av hybrid polypeptid og dna-molekyl for bruk i denne
EP0676413A3 (en)	1996-04-03	Interferon alpha / beta binding protein, its production and application.
DE59106997D1 (de)	1996-01-11	Ancrod ähnliche proteine, ihre herstellung und verwendung.